Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
